Hypertrophic cardiomyopathy: The importance of arrhythmic events in patients at risk for sudden cardiac death;Cardiomiopatia hipertrófica: Importância dos eventos arrítmicos em pacientes com risco de morte súbita

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 5, 2006, Pages

  Medeiros, Paulo De Tarso Jorge ^a,b   Martinelli Filho, Martino ^a   Arteaga, Edmundo ^a   Costa, Roberto ^a   Siqueira, Sérgio ^a   Mady, Charles ^a   Piegas, Leopoldo Soares ^a   Ramires, José Antonio Franchini ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Arrhythmia; Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Risk factors; Sudden cardiac death

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CONVULSIVE THERAPY; DEFIBRILLATION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PROGNOSIS; RISK ASSESSMENT; STROKE; SUDDEN DEATH; SYNCOPE; THROMBOEMBOLISM; ADOLESCENT; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ARRHYTHMIA; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 33846385042     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2006001800016     Document Type: Article

References (29)

1. Tirone AP, Arteaga E. Cardiomiopatia hipertrófica familiar, caracterização genética. Arq Bras Cardiol 1999; 72 (4): 517-19.
2. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-75.
3. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol 1995; 18: 189-98.
4. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999; 281 (18): 1746-52.
5. Arteaga E. História natural e fatores prognósticos na cardiomiopatia hipertrófica. Rev Soc Cardiol Estado de São Paulo 2000; 10 (4): 462-69.
6. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003; 42 (9): 1687-713.
7. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-91.
8. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-85.
9. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002; 287: 1308-20.
10. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-64.
11. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36 (7): 2212-18.
12. Maron BJ, Estes III M, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872-75.
13. Maron BJ. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter- defibrillator (Hotline Editorial). Eur Heart J. 2000; 21 (24): 1979-83.
14. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J 1994; 72 (Supplement): S13-S18.
15. Rocha Neto AC, Mesas CE, Farias RL, de Paola AAV. Arritmias ventriculares e morte súbita na cardiomiopatia hipertrófica. Rev Soc Cardiol Estado de São Paulo 2000; 10 (4): 480-6.
16. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, et al. Prognosis asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-47.
17. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-16.
18. Begley DA, Mohiddin AS, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. PACE 2003; 26: 1887-96.
19. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JM, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-73.
20. Jayatilleke I, Doolan A, Igles J, McGuire M, Booth V, Richmond DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004; 93: 1192-94.
21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The commitee on M-mode standardization of American Society of Echocardiography: results of a survey of echocardiography measurements. Circulation 1978; 58: 1072-83.
22. Morcerf FAP. Ecocardiografia uni-bidimensional, transesofágica e Doppler. 2a ed. Rio de Janeiro: Revinter; 2001. Cap. 13, p. 462-84: Miocardiopatias.
23. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7-11.
24. Diretrizes para avaliação e tratamento de pacientes com arritmias cardíacas. Arq Bras Cardiol 2002; 79: (suplemento V).
25. Vieira S. Introdução à bioestatística. 3a ed. Rio de Janeiro: Campus; 1998.
26. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Science; 1994.
27. Favale S, Pappone C, Nacci F, Fino F, Resta F, Dicandia CD. Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient. PACE 2003; 26: 637-39.
28. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86: 730-40.
29. McKenna WJ, Monserrat Iglesias L. Identificatión y tratamiento de los pacientes com miocardiopatía hipertrófica y riesgo de muerte súbita. Rev Esp Cardiol 2000; 53: 123-30.